Skip to main content
TipRanks
Go Ultimate75% OFF

Karyopharm Therapeutics (KPTI) Stock Statistics & Valuation Metrics

3 Followers

Total Valuation

Karyopharm Therapeutics has a market cap or net worth of CHF 483.43K. The enterprise value is CHF 473.81M.

Market Cap
CHF 483.43K
Enterprise Value
CHF 473.81M

Share Statistics

Karyopharm Therapeutics has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
―
Owned by Insiders
3.63%
Owned by Institutions
33.45%

Financial Efficiency

Karyopharm Therapeutics’s return on equity (ROE) is 0.67 and return on invested capital (ROIC) is -236.62%.

Return on Equity (ROE)
0.67
Return on Assets (ROA)
-1.81
Return on Invested Capital (ROIC)
-236.62%
Return on Capital Employed (ROCE)
-5.55
Revenue Per Employee
640.64K
Profits Per Employee
-859.82K
Employee Count
228
Asset Turnover
1.35
Inventory Turnover
1.47

Valuation Ratios

The current PE Ratio of Karyopharm Therapeutics is -0.00. Karyopharm Therapeutics’s PEG ratio is 0.00.

PE Ratio
-0.00
PS Ratio
0.00
PB Ratio
-0.00
Price to FCF
-0.01
Price to Operating Cash Flow
-0.01
PEG Ratio
0.00

Income Statement

In the last 12 months, Karyopharm Therapeutics had revenue of 146.07M and earned -196.04M in profits. Earnings per share was -17.93.

Revenue
146.07M
Gross Profit
140.12M
Operating Income
-90.71M
Pretax Income
-196.00M
Net Income
-196.04M
EBITDA
-149.85M
Earnings Per Share (EPS)
-17.93

Cash Flow

In the last 12 months, operating cash flow was -65.35M and capital expenditures 0, giving a free cash flow of -65.35M billion.

Operating Cash Flow
-65.35M
Free Cash Flow
-65.35M
Free Cash Flow per Share
-2.26

Dividends & Yields

Karyopharm Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-12977.83%
Earnings Yield
-34983.15%

Important Dates

Karyopharm Therapeutics upcoming earnings date is Feb 10, 2027, TBA (Not Confirmed).

Last Earnings Date
Oct 29, 2026
Next Earnings Date
Feb 10, 2027
Ex-Dividend Date
―

Financial Position

Karyopharm Therapeutics as a current ratio of 1.12, with Debt / Equity ratio of -79.75%

Current Ratio
1.12
Quick Ratio
1.08
Debt to Market Cap
2.82
Net Debt to EBITDA
-1.15
Interest Coverage Ratio
-1.98

Taxes

In the past 12 months, Karyopharm Therapeutics has paid 43.00K in taxes.

Income Tax
43.00K
Effective Tax Rate
-0.00

Enterprise Valuation

Karyopharm Therapeutics EV to EBITDA ratio is -0.92, with an EV/FCF ratio of -2.47.

EV to Sales
1.10
EV to EBITDA
-0.92
EV to Free Cash Flow
-2.47
EV to Operating Cash Flow
-2.47

Balance Sheet

Karyopharm Therapeutics has CHF 65.11M in cash and marketable securities with CHF 215.88M in debt, giving a net cash position of -CHF 150.78M billion.

Cash & Marketable Securities
CHF 65.11M
Total Debt
CHF 215.88M
Net Cash
-CHF 150.78M
Net Cash Per Share
―
Tangible Book Value Per Share
-CHF 11.41

Margins

Gross margin is 95.88%, with operating margin of -56.17%, and net profit margin of -153.28%.

Gross Margin
95.88%
Operating Margin
-56.17%
Pretax Margin
-153.30%
Net Profit Margin
-153.28%
EBITDA Margin
-119.94%
EBIT Margin
-120.04%

Analyst Forecast

The average price target for Karyopharm Therapeutics is CHF 4.88, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target
CHF 4.88
Price Target Upside
―
Analyst Consensus
Moderate Buy
Analyst Count
3
Revenue Growth Forecast
―
EPS Growth Forecast
―